Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiora Pharmaceuticals filings document a clinical-stage ophthalmology issuer focused on small-molecule programs for retinal disease. Current disclosures cover results of operations and financial condition, research-and-development progress for KIO-301 and KIO-104, collaboration reimbursements, and clinical or regulatory updates tied to the company’s development pipeline.
Material-event reports also record securities purchase agreements, common stock, pre-funded warrants and Tranche A warrants issued in private placements, along with executive changes. Proxy materials address board governance, executive compensation, equity awards, shareholder voting matters and related risk-factor disclosures for a Nasdaq-listed Delaware corporation.
Kiora Pharmaceuticals, Inc. (KPRX) entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation (CKD) covering its KIO-301 molecular photoswitch program. CKD receives an exclusive, sublicensable license to develop, manufacture, commercialize and seek regulatory approvals for KIO-301 in South Korea for retinitis pigmentosa and other ophthalmic diseases.
Under the agreement, Kiora will receive a $1 million up-front payment and is eligible for additional development, regulatory and sales milestone payments, plus double digit royalties on net sales in South Korea, subject to adjustments. CKD will lead development and commercialization in South Korea, while Kiora expects CKD, Laboratoires Théa and Senju Pharmaceutical to coordinate a single global Phase 3 trial for KIO-301 in retinitis pigmentosa.
Kiora highlights that this deal fills the last major unpartnered market for KIO-301 and allows internal resources to focus on KIO-104 for retinal inflammation and fibrosis and evaluation of ion channel modulators for non-ophthalmic uses, alongside potential strategic pipeline-expansion transactions.
ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC and Daniel Schneeberger report beneficial ownership of Kiora Pharmaceuticals common stock. Each Reporting Person discloses beneficial ownership of approximately 9.9% of the outstanding common stock, based on 4,427,167 shares outstanding as of June 30, 2026.
The reported positions include combinations of directly held shares and shares underlying pre-funded and milestone warrants, while additional warrant shares are excluded due to a 9.99% beneficial ownership limitation. Schneeberger files as a control person over the ADAR1 entities.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of Kiora Pharmaceuticals, Inc. common stock. As of June 30, 2026, they may be deemed to beneficially own 491,889 shares, including shares acquirable within sixty days through convertible securities. This position represents 9.99% of Kiora’s outstanding common stock for each reporting person. All voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, has rights to receive dividends or sale proceeds on more than five percent of the outstanding common stock included in this beneficial ownership.
Kiora Pharmaceuticals, Inc. is reported to have 9.99% of its common stock beneficially owned by Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd., acting together. This filing corrects and restates a prior ownership report that was submitted under an incorrect Central Index Key.
The Master Fund directly holds 438,471 shares of common stock, pre-funded warrants to purchase 1,134,474 shares at an exercise price of $0.0001 per share, and common warrants to purchase 7,864,726 shares at $1.94 per share. Warrant terms limit exercises so that the reporting group cannot beneficially own more than 9.99% of the outstanding shares, which currently permits exercise of warrants for up to 3,916 shares. Reported ownership and percentages are based on 4,424,387 shares of common stock outstanding as of August 5, 2026.
Kiora Pharmaceuticals reported financial results for the second quarter ended June 30, 2026, alongside updates on its retinal-disease pipeline. Enrollment has advanced into the higher 100 µg dose cohort of the Phase 2 ABACUS-2 trial of KIO-301 for late-stage retinitis pigmentosa, with an independent safety review planned after the first few higher-dose patients are treated. The company expects the last patient, first visit in the first quarter of 2027 and topline data in the third quarter of 2027. Development costs for ABACUS-2 are fully reimbursed under Kiora’s collaboration with Théa Open Innovation, which holds exclusive rights to KIO-301 in the U.S., Europe and other select territories outside Asia.
For KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation and macular edema, patients are being enrolled into the higher-dose group of the Phase 2 KLARITY trial, with initial clinical data expected in late 2026. Kiora is also evaluating potential strategic transactions to diversify its pipeline, which could trigger warrant exercises linked to a recent financing, and is assessing partnering options across Asian territories, including an option agreement with Senju and a potential commercial partner in South Korea.
Kiora ended the quarter with approximately $16.8 million in cash and short-term investments, up from $13.9 million at March 31, 2026, and has secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million already received. Based on its operating plan, collaboration reimbursements and available capital, the company expects to fund operations into late 2028. Research and development expenses were $2,077,116 before $1,336,263 in collaboration credits, general and administrative expenses were $1,383,504, and net loss was $2,079,010, or $0.34 per share, for the second quarter of 2026.
Kiora Pharmaceuticals, a clinical-stage ophthalmic company, reported a net loss of $2,079,010 for the quarter and $4,496,994 for the six months ended June 30, 2026. Quarterly operating expenses were $2.2M, including $2.1M of research and development, partially offset by $1.3M of collaboration credits from the KIO‑301 partnership.
Cash, cash equivalents and restricted cash totaled $7.1M and short-term investments $9.8M as of June 30, 2026, with total assets of $23.8M and stockholders’ equity of $16.9M. Management states that, based on these cash resources, it anticipates funding planned operations into late 2028 and does not currently anticipate an immediate need to raise additional capital.
The pipeline centers on KIO‑301, a potential vision-restoring small-molecule photoswitch for degenerative retinal diseases partnered with Théa Open Innovation, and KIO‑104, an intravitreal DHODH inhibitor in Phase 2 for retinal inflammation. Under the Théa license, all KIO‑301 research and development costs are reimbursed.
Kiora Pharmaceuticals CFO Melissa Tosca reported a small insider transaction involving company common stock. On July 1, 2026, 911 shares were disposed of at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to satisfy tax obligations rather than sold on the open market. Following this transaction, Tosca directly holds 26,064 shares of Kiora Pharmaceuticals common stock.
Kiora Pharmaceuticals' President and CEO Brian M. Strem reported a small share disposition related to taxes. On July 1, 2026, he had 1,869 shares of Kiora common stock transferred at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold on the open market. After this transaction, he directly owns 58,823 common shares, so the adjustment represents a minor change in his overall stake.
Kiora Pharmaceuticals filed a current report describing new preclinical data for its ion channel modulator platform. The company reported that KIO-300, the active ingredient in its Phase 2 vision restoration drug KIO-301, significantly suppressed seizure-associated electrical activity in an ex vivo temporal lobe epilepsy model.
The effect reduced spontaneous epileptiform event frequency versus vehicle controls and remained during treatment and washout, while broader electrical transmission in brain tissue was preserved. These findings, presented at the Epilepsy Foundation Pipeline Conference, support potential applications of KIO-300 in epilepsy and other neurological disorders beyond ophthalmology.
Kiora Pharmaceuticals director Carmine N. Stengone received a stock option grant as part of equity compensation. On June 10, 2026, he was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, with no cash paid for the grant itself.
The options were granted under Kiora’s 2024 Equity Incentive Plan and will become fully exercisable on June 10, 2027. They expire on June 10, 2036 if not exercised. After this award, Stengone holds options for 25,000 underlying shares directly, and the filing does not report any open‑market purchases or sales.